Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy - A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

Clinical Diabetes

Volumn 27, Issue 1, 2009, Pages 4-16

  Nathan, David M ^a   Buse, John B ^b   Davidson, Mayer B ^c   Ferrannini, Ele ^d   Holman, Rury R ^e   Sherwin, Robert ^f   Zinman, Bernard ^g  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^d UNIVERSITY OF PISA   (Italy)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; CHLORPROPAMIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN; METFORMIN; NATEGLINIDE; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

ALGORITHM; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONSENSUS DEVELOPMENT; DIARRHEA; DIET RESTRICTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FLUID RETENTION; FRACTURE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; GOAL ATTAINMENT; HEALTH CARE ORGANIZATION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LIFESTYLE MODIFICATION; MONOTHERAPY; MORNING DOSAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; SIDE EFFECT; TREATMENT PLANNING; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 59349100028     PISSN: 08918929     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaclin.27.1.4     Document Type: Conference Paper

References (92)

1. American Diabetes Association: Standards of medical care in diabetes - 2008 (Position Statement). Diabetes Care 31(Suppl. 1): S12-S54, 2008
2. European Diabetes Policy Group: A desk-top guide to type 2 diabetes mellitus. Diabet Med 16:716-730, 1999
3. National Institute for Clinical Excellence: Clinical guidelines for type 2 diabetes mellitus: management of blood glucose [article online], 2002. Available from http://www.nice.org.uk./Guidancet/CG66
4. Diabetes Control and Complications Trial Research Group: The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. N Engl J Med 329:978-986, 1993
5. Reichard P, Nilsson B-Y, Rosenqvist U: The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304-309, 1993
6. U.K. Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
7. U.K. Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
8. Ohkubo Y, Kishikawa H, Araki E, et al.: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with NIDDM: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995
9. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes. N Engl J Med 348:2294-2303, 2003
10. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643-2653, 2005
11. The Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545-2559, 2008
12. The ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560-2572, 2008
13. Abraira C, Duckworth WC, Moritz T: Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes Obes Metab. 29 July 2008 [Epub ahead of print]
14. Nathan DM: Finding new treatments for diabetes - how many, how fast . . . how good? N Engl J Med 356:437-440, 2007
15. Nathan DM: Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 347:1342-1349, 2002
16. Sheehan MT: Current therapeutic options in type 2 diabetes mellitus: a practical approach. Clin Med Res 1:189-200, 2003
17. Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes. JAMA 287:360-372, 2002
18. Klein R, Klein BEK, Moss SE, et al.: Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 260:2864-2871, 1988
19. Chase HP, Jackson WE, Hoops SL, et al.: Glucose control and the renal and retinal complications of insulin-dependent diabetes. JAMA 261:1155-1160, 1989
20. Little RR, Rohlfing CL, Wiedmeyer H-M, et al.: The National Glycohemoglobin Standardization Program (NGSP): a five year progress report. Clin Chem 47:1985-1992, 2001
21. Grundy SM, Cleeman JI, Merz NB, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227-239, 2004
22. Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289:2560-2572, 2003
23. DCCT Research Group: The association between glycemic exposure and long-term diabetic complications in the Diabetes Control and Complications Trial. Diabetes 44:968-983, 1995
24. Stratton IM, Adler AI, Neil HA, et al.: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
25. National Institutes of Health: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: the Evidence Report. Bethesda, MD, National Heart, Lung, and Blood Institute, National Institutes of Health, 1999
26. Groop L: Sulfonylureas in NIDDM. Diabetes Care 15:737-747, 1992
27. Bailey CJ, Turner RC: Metformin. N Engl J Med 334:574-583, 1996
28. Malaisse WJ: Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treat Endocrinol 2:401-414, 2003
29. Van de Laar FA, Lucassen PL, Akkermans RP, et al.: Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2:CD003639, 2005
30. Genuth S: Insulin use in NIDDM. Diabetes Care 13:1240-1264, 1990
31. Yki-Jarvinen H: Drug therapy: thiazolidinediones. N Engl J Med 351:1106, 2004
32. Drucker DJ: Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nature Endocrinol Metab 1:22-31, 2005
33. Schmitz O, Brock B, Rungby J: Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 53 (Suppl. 3):S233-S238, 2004
34. Richter B, Bandeira-Echtler E, Bergerhoff K, et al.: Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2:CD006739, 2008
35. Amori RE, Lau J, Pittas AG: Efficacy and safety of incretin therapy in type 2 diabetes: a systematic review and meta-analysis. JAMA 298:194-206, 2007
36. Monami M, Lamannac C, Marchionni N, et al.: Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 79:196-203, 2008
37. Bolen S, Feldman L, Vassy J, et al.: Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147:386-399, 2007
38. Colagiuri S, Cull CA, Holman RR, et al.: Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? U.K. Prospective Diabetes Study 61. Diabetes Care 25:1410-1417, 2002
39. Harris MI: Epidemiologic correlates of NIDDM in Hispanics, whites and blacks in the U.S. population. Diabetes Care 14 (Suppl. 3):639-648, 1991
40. Rewers M, Hamman RF: Risk factors for non-insulin dependent diabetes. In Diabetes in America. 2nd ed. Harris M, Ed. Bethesda, MD, National Institutes of Health, 1995, p. 179-220 (NIH publ. no. 95-1468)
41. Look AHEAD Research Group: Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care 30:1374-1383, 2007
42. Pories WJ, Swanson MS, MacDonald KG, et al.: Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222:339-350, 1995
43. Sjostrom L, Lindroos AK, Peltonen M, et al.: Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351:2683-2693, 2004
44. Dixon JB, O'Brien PE, Playfair J, et al.: Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 299:316-323, 2008
45. Pontiroli AE, Folli F, Paganelli M, et al.: Laparoscopic gastric banding prevents type 2 diabetes and arterial hypertension and induces their remission in morbid obesity: a 4-year case-controlled study. Diabetes Care 28:2703-2709, 2005
46. Diabetes Prevention Program Research Group: Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care 28:888-894, 2005
47. Hadden DR, Montgomery DAD, Skelly RJ, et al.: Maturity onset diabetes mellitus: response to intensive dietary management. BMJ 3:276-278, 1975
48. Peters AL, Davidson MB: Maximal dose glyburide in markedly symptomatic patients with type 2 diabetes: a new use for an old friend. J Clin Endocrinol Metab 81:2423, 1996
49. DeFronzo R, Goodman A, the Multicenter Metformin Study Group: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:541-549, 1995
50. Diabetes Prevention Program Research Group: Reduction in incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
51. Salpeter S, Greyber E, Pasternak G, et al.: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 1:CD002967, 2006
52. Shaw JS, Wilmot RL, Kilpatrick ES: Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med 24:1160-1163, 2007
53. Holstein A, Plaschke A, Egberts E-H: Lower incidence of severe hypoglycemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 17:467-473, 2001
54. Gangji AS, Cukierman T, Gerstein HC, et al.: A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 30:389-394, 2007
55. Kahn SE, Haffner SM, Heise MA, et al.: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443, 2006
56. Meinert CL, Knatterud GL, Prout TE, et al.: The University Group Diabetes Program: a study of the effect of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 19 (Suppl. 1):789-830, 1970
57. Rosenstock J, Hassman DR, Madder RD, et al.: Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 27:1265-1270, 2004
58. Gerich J, Raskin P, Jean-Louis L, et al.: PRESERVE-beta: two year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 28:2093-2099, 2005
59. Damsbo P, Clauson P, Marbury TC, et al.: A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care 22:789-794, 1999
60. Chiasson JL, Josse RG, Gomis R, et al.: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM Trial. JAMA 290:486-494, 2003
61. Home PD, Pocock SJ, Beck-Nielsen H, et al.: Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 357:28-38, 2007
62. Singh S, Loke YK, Furberg CD: Thiazolidinediones and heart failure: a teleoanalysis. Diabetes Care 30:2248-2254, 2007
63. Khan MA, St Peter JV, Xue JL: A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 25:708-711, 2002
64. Goldberg RB, Kendall DM, Deeg MA, et al.: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28:1547-1554, 2005
65. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-2471, 2007
66. Singh S, Loke YK, Furberg CD: Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298:1189-1195, 2007
67. Dormandy JA, Charbonnel B, Eckland DJA, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive (PROspective pioglitAzone Clinical Trial in macrovascular Events): a randomized controlled trial. Lancet 366:1279-1289, 2005
68. Lincoff AM, Wolski K, Nicholls SJ, et al.: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298:1180-1188, 2007
69. Nathan DM, Buse JB, Davidson MB, et al.: Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding the thiazolidinediones. Diabetologia 51:8-11, 2008
70. Meier C, Kraenzlin ME, Bodmer M, et al.: Use of thiazolidinediones and fracture risk. Arch Intern Med 168:820-825, 2008
71. Horvath K, Jeitler K, Berghold A, et al.: Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2:CD005613, 2007
72. Raskin P, Allen E, Hollander P: Initiating insulin therapy in type 2 diabetes. Diabetes Care 28:260-265, 2005
73. Dailey G, Rosenstock J, Moses RG, et al.: Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 27:2363-2368, 2004
74. Nathan DM, Roussell A, Godine JE: Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus: a randomized double-blind study. Ann Intern Med 108:334-340, 1998
75. Abraira C, Johnson N, Colwell J, et al.: VA Cooperative study on glycemic control and complications in type II diabetes. Diabetes Care 18:1113-1123, 1995
76. Zammitt NN, Frier BM: Hypoglycemia in type 2 diabetes. Diabetes Care 28:2948-2961, 2005
77. Miller CD, Phillips LS, Ziemer DC, et al.: Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 161:1653-1659, 2005
78. Kendall DM, Riddle MC, Rosenstock J, et al.: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28:1083-1091, 2005
79. DeFronzo RA, Ratner RE, Han J, et al.: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28:1092-1100, 2005
80. Buse JB, Henry RR, Han J, et al.: Effects of exenatide on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27:2628-2635, 2005
81. Heine RJ, Van Gaal LF, Johns D, et al.: Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med 143:559-569, 2005
82. Riddle M, Frias J, Zhang B, et al.: Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care 30:2794-2799, 2007
83. Raz I, Hanefeld M, Xu L, et al.: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49:2564-2571, 2006
84. Goldstein B, Feinglos M, Lunceford J, et al.: Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 30:1979-1987, 2007
85. Welschen LMC, Bloemendal E, Nijpels G, et al.: Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. Diabetes Care 28:1510-1517, 2005
86. Farmer A, Wade A, Goyder E, et al.: Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ 335:132, 2007
87. Ilkova H, Glaser B, Tunckale A, et al.: Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 20:1353-1356, 1997
88. Weng J, Li Y, Xu W, et al.: Effect of intensive insulin therapy on beta-cell function and glycemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomized parallel-group trial. Lancet 371:1753-1760, 2008
89. U.K. Prospective Diabetes Study Group: U.K. Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44:1249-1258, 1995
90. Hirsch IB, Bergenstal RM, Parkin CG, et al.: A real-world approach to insulin therapy in primary care practice. Clinical Diabetes 23:78-86, 2005
91. Schwartz S, Sievers R, Strange P, et al.: Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs. Diabetes Care 26:2238-2243, 2003
92. Yki-Jarvinen H, Ryysy L, Nikkila K, et al.: Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. Ann Intern Med 130:389-396, 1999